SCHEMBL22649593

SCHEMBL22649593

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCCN1CCN(CCCC(=O)O)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 12/20 0.79
KDR P35968 10/20 0.79
FGFR1 P11362 8/20 0.79
TLK2 Q86UE8 5/20 0.79
HDAC3 O15379 3/20 0.72
HDAC4 P56524 3/20 0.72
HDAC1 Q13547 3/20 0.72
HDAC7 Q8WUI4 3/20 0.72
HDAC2 Q92769 3/20 0.72
HDAC10 Q969S8 3/20 0.72
HDAC11 Q96DB2 3/20 0.72
HDAC8 Q9BY41 3/20 0.72
HDAC6 Q9UBN7 3/20 0.72
HDAC9 Q9UKV0 3/20 0.72
HDAC5 Q9UQL6 3/20 0.72
PRKAA1 Q13131 8/20 0.70
PRKAA2 P54646 7/20 0.70
PLK4 O00444 3/20 0.66
DCLK1 O15075 3/20 0.66
PDPK1 O15530 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22649616 0.94 PDGFRB (0.79) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL31672543 0.93 PDGFRB (0.83) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL2117022 0.93 PDGFRB (0.83) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL22649613 0.92 PDGFRB (0.72) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL22649591 0.91 PDGFRB (0.81) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL22649609 0.91 PDGFRB (0.81) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL4016628 0.90 PDGFRB (0.84) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL1625556 0.90 PDGFRB (0.84) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL1625652 0.90 PDGFRB (0.84) PDGFRBKDRFGFR1TLK2HDAC3
SCHEMBL1625555 0.90 PDGFRB (0.84) PDGFRBKDRFGFR1TLK2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230022524-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-01-26 US disclosed
WO-2020227325-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022524-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 HIPK1, MCL1, HYPK PDGFRB 832/4885KDR 1242/4885FGFR1 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.